"Ki-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D017730
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.072 D23.050.285.025 D23.101.140.055
|
| Concept/Terms |
Ki-1 Antigen- Ki-1 Antigen
- Antigen, Ki-1
- Ki 1 Antigen
- CD30 Antigens
- Antigens, CD30
- Ber-H2 Antigen
- Antigen, Ber-H2
- Ber H2 Antigen
- TNFRSF8 Receptor
- Receptor, TNFRSF8
- Antigens, Ki-1
- Antigens, Ki 1
- Ki-1 Antigens
- Ki 1 Antigens
- Tumor Necrosis Factor Receptor Superfamily, Member 8
- CD30 Antigen
- Antigen, CD30
- Ber-H2 Antigens
- Antigens, Ber-H2
- Ber H2 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Ki-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-1 Antigen".
This graph shows the total number of publications written about "Ki-1 Antigen" by people in this website by year, and whether "Ki-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-1 Antigen" by people in Profiles.
-
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV?+?lymphomas. Leuk Lymphoma. 2021 12; 62(14):3493-3500.
-
Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype. Am J Clin Dermatol. 2016 Feb; 17(1):71-7.
-
Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin. Carcinogenesis. 2003 Feb; 24(2):301-6.